
Tech-enabled vision care startup Eyebot has secured $20 million in Series A funding to expand its fast-growing network of self-service vision test kiosks. The round was led by General Catalyst, with backing from existing investors AlleyCorp, Baukunst, Village Global, and Ubiquity Ventures.
The new capital comes as Eyebot scales its model across retail, university, and grocery store locations, offering quick, cost-free vision tests verified by licensed doctors.
Eyebot sits at the intersection of healthcare and convenience retail, tapping into a vast unmet need. In the U.S., millions forgo vision care due to cost, scheduling issues, or geographic access. Eyebot’s kiosks aim to close this gap by offering 90-second, no-appointment vision tests—generating doctor-reviewed prescriptions without insurance or paperwork.
"Clear vision shouldn't require months of waiting, high costs, or geographic luck," said Matthias Hofmann, co-founder and CEO of Eyebot. "This funding will help us accelerate our expansion, strengthen our clinical partnerships, and bring accessible vision care to millions more people."
Eyebot plans to use the new funds to roll out hundreds of additional kiosks across retail environments nationwide, while also growing its engineering and clinical teams. By embedding kiosks in places people already visit—like shopping centers, pharmacies, and universities—the company aims to remove friction from basic eye care.
Beyond physical expansion, Eyebot is doubling down on product development and deeper partnerships with retailers and private practices. Several new launches are expected later this year, including collaborations with national brands.
Founded to make vision care more accessible, Eyebot is not aiming to replace doctors—but to work alongside them. Each kiosk-administered test is reviewed by a licensed professional, and the company’s platform is built with clinical oversight as a core principle.
Eyebot has completed more than 45,000 tests to date, and is on track to perform over 500,000 annually. The company has also validated its technology through IRB-approved studies involving 2,500+ patients, showing comparable accuracy to in-person exams—and higher satisfaction scores.
To support this clinical framework, Eyebot recently formed a Clinical Advisory Board, led by Chief Medical Officer Dr. Alexander Martin, with members from both optometry and ophthalmology.
More than 3 million Americans live with vision impairment, and another 8 million have undiagnosed or uncorrected refractive errors like nearsightedness. Eyebot targets this large and underserved population with a simple proposition: make basic eye care as easy as picking up groceries.
"Wider access to high quality eye screenings will lead to more doctor visits, which in turn will allow for earlier detection of diseases and save sight," said Dr. Martin.
Eyebot’s platform also offers new value to both emerging and established eyewear retailers. For startups, the kiosks serve as a low-footprint entry into physical retail; for legacy players, they offer a way to scale capacity without building new infrastructure.
General Catalyst led the Series A, joining a cohort of investors who have supported Eyebot since its early days. Returning investors include AlleyCorp, Baukunst, Village Global, and Ubiquity Ventures.
"We invested in Eyebot because they've built something simple, scalable, and incredibly impactful," said Caitlin Donovan, Partner at General Catalyst. "They're tackling a real access challenge in healthcare and doing it in a way that supports clinicians, retailers, and consumers alike."

